Decoy Therapeutics (DCOY) Director Paul Lammers Receives Award

What Happened Paul Lammers, a director of Decoy Therapeutics, was granted 2,000 restricted shares on August 31, 2026. The award was reported as an acquisition at $0.00 per share (total reported cost $0) under the company's 2026 Equity Incentive Plan. The shares are restricted stock rather than an open‑market purchase.

Key Details

• Transaction date: 2026-08-31; Form 4 filed 2026-09-02 (appears timely; Form 4 is generally due within two business days).
• Transaction type/code: Award/Grant (A); 2,000 shares acquired at $0.00 (total $0 reported).
• Vesting: 100% of the restricted shares vest on August 30, 2027 (footnote F1).
• Post-transaction beneficial ownership: the filing notes that shares beneficially owned were adjusted for reverse stock splits effective Aug 15, 2025 and Mar 6, 2026 (footnote F2). See the full filing for the exact post‑transaction ownership total.
• No 10b5-1 plan, cashless exercise, sale, or tax‑withholding sale is indicated in the provided notes.

Context This grant is a compensation award (restricted stock) with a one‑year vesting cliff, not a market purchase or sale; such awards compensate or retain insiders and do not by themselves signal a buy/sell decision. Retail investors should view it as an executive compensation event—useful for tracking insider alignment but not a direct market purchase.